Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature by Visser, K & van der Heijde, D
Optimal dosage and route of administration of
methotrexate in rheumatoid arthritis: a systematic
review of the literature
K Visser, D van der Heijde
c Additional appendices are
published online only at http://
ard.bmj.com/content/vol68/
issue7
Department of Rheumatology,
Leiden University Medical
Center, Leiden, The Netherlands
Correspondence to:
Dr K Visser, Leiden University
Medical Center, Department of
Rheumatology, C1-R, PO Box
9600, 2300 RC Leiden, The
Netherlands; K.Visser@lumc.nl
Accepted 17 November 2008
Published Online First
25 November 2008
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
ard.bmj.com/info/unlocked.dtl
ABSTRACT
Objectives: To review systematically the available
literature on the optimal dosage and route of adminis-
tration of methotrexate in patients with rheumatoid
arthritis (RA), as an evidence base for generating clinical
practice recommendations.
Methods: A systematic literature search was carried out
in MEDLINE, EMBASE, Cochrane Library and American
College of Rheumatology/European League Against
Rheumatism meeting abstracts, searching for randomised
controlled trials evaluating various dosages or routes of
administration of methotrexate in RA. Articles that fulfilled
predefined inclusion criteria were systematically reviewed
and the quality was appraised. Effect sizes and odds
ratios for clinical, radiological and toxicity outcomes were
calculated and directly or indirectly compared between
study groups using methotrexate in different dosages or
by different routes.
Results: A total of 38 publications out of 1748 identified
references was included in the review. Start doses of
25 mg/week or fast escalation with 5 mg/month to 25–
30 mg/week were associated with higher clinical effect
sizes and more (gastrointestinal) adverse events in
comparison with doses of 5–15 mg/week or slow
escalation. Starting with 15 mg/week subcutaneous
versus oral methotrexate was associated with higher
clinical efficacy but more withdrawal due to toxicity in
early RA. In longstanding RA, after failure on 15–20 mg/
week orally, a switch to 15 mg/week intramuscularly with
subsequent dose escalation did not result in increased
efficacy.
Conclusions: Starting on methotrexate 15 mg/week
orally, escalating with 5 mg/month to 25–30 mg/week,
or the highest tolerable dose, with a subsequent switch to
subcutaneous administration in the case of an insufficient
response, seems to be the optimal evidence-based dosing
and routing recommendation for methotrexate in RA.
Methotrexate is widely used as the disease
modifying antirheumatic drug (DMARD) of first
choice in the treatment of rheumatoid arthritis
(RA), because it is effective, has an acceptable
toxicity profile and has low costs.
1–3 Despite more
than two decades of experience, considerable
variability exists in the way rheumatologists
prescribe methotrexate therapy, including the
dosage and route of administration. More knowl-
edge on the optimal use is needed, as this would
benefit RA patients, improve education and facil-
itate treatment evaluation.
This paper is part of the 3E (evidence,
expertise, exchange) Initiative. This 3E Initiative
and the resulting recommendations for the use of
methotrexate are described in more detail in the
same issue of this journal.
4 The objective of the
current work was to review systematically the
available literature concerning one of the 10
selected questions as an evidence base for generat-
ing the recommendations. The question was:
‘‘What is the best dosing strategy and route of
administration of methotrexate in patients with
RA to optimise rapid, early, clinical and radio-
graphic response and minimise toxicity?’’
METHODS
The systematic literature review was carried out in
several steps following the updated guidelines for
Cochrane systematic reviews.
5
Rephrasing research question
The clinical question as formulated by the experts
was translated into an epidemiological research
question according to the PICO (patient, interven-
tion, comparator, outcome) method.
6 Patients were
defined as adults with RA according to the
American College of Rheumatology (ACR) cri-
teria.
7 The intervention was defined as methotrex-
ate in a certain dosage (separate for start,
escalation and target dose) and a certain route of
administration (oral, subcutaneous, intramuscular
or intravenous), with a different dosage or route as
comparator. Outcomes were threefold: clinical
efficacy measures among swollen joint count
(SJC), tender joint count (TJC), disease activity
score (DAS), ACR20/50/70 response, visual analo-
gue scale for patient-reported outcomes, health
assessment questionnaire and erythrocyte sedi-
mentation rate; radiological progression and sys-
tem-specific adverse events including withdrawal
due to toxicity. Effect sizes and odds ratios (OR)
were anticipated effect parameters. The final
search question was thus rephrased as: What is
the difference in effect size and OR for short-term
clinical, radiographic and toxicity outcomes in RA
patients on various dosages and routes of admin-
istration of methotrexate?
Scenarios
In the optimal scenario we anticipated to find
randomised controlled trials (RCT) directly com-
paring different dosages or routes of methotrexate
administration. The suboptimal scenario included
RCT evaluating methotrexate monotherapy versus
placebo, another DMARD, a biological, or a
combination of DMARD without methotrexate.
By grouping the trials per comparator drug,
potential indirect comparisons between various
Extended report
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these indirect comparisons was a homogeneous response in the
comparator arms within the grouped trials. Observational
studies represented the least optimal scenario, as these
inherently introduce methodological limitations.
Systematic literature search
A systematic literature search for articles published between
1950 and September 2007 was carried out in MEDLINE,
EMBASE and the Cochrane Library, using a comprehensive
search strategy (appendix 1 of the online only version of this
paper) in collaboration with an experienced librarian.
13 The
European League Against Rheumatism (EULAR) 2005–7 and
ACR 2005–6 meeting abstracts were also searched. The search
was limited to RCT, using a modification of the Cochrane
highly sensitive search strategy.
14 No language restriction was
used. Review articles were also retrieved for identifying
additional references via hand search.
Selection of articles
Relevant articles were selected in a systematic two-step
procedure. First, titles and abstracts of all identified references
were screened, excluding articles that clearly did not address the
topic of interest. Second, selected articles were reviewed in full
paper, applying the following inclusion criteria: RCT, RA
18 years old or greater, monotherapy methotrexate in one of
the treatment groups, data on dosage and route and data on one
or more of the prespecified outcome measures. Articles that did
not fulfil all the inclusion criteria or had insufficient data for
analysis were excluded from the systematic review.
Data extraction and quality appraisal
Publication details, patient characteristics, dosage and route of
methotrexate and data on relevant outcomes were extracted
from all the included articles using standard forms. Data from
non-English language publications were extracted by reviewers
from the international panel of the 3E Initiative. If necessary,
authors were contacted to provide additional information. The
methodological quality of each RCT was graded by a scale
according to van Tulder et al,
5 with a maximum score of 11
points. The points were subsequently translated into levels of
evidence according to the Oxford Centre for Evidence-based
Medicine,
15 a summary of which can be found in appendix 2 of
the online version of this paper.
Data-analysis
For continuous variables, three types of effect size were
calculated for the difference between baseline and the end of
trial data.
16 17 Per treatment group, the effect size and the
standardised response mean (SRM) were calculated as the mean
change in score divided by the baseline standard deviation (SD)
(effect size) or the mean change divided by the SD of the change
(SRM). To compare the effect between two treatment groups,
the pooled Cohen’s effect size was calculated as the mean
change in the index group minus the mean change in the
comparator group divided by a pooled baseline SD. The
corresponding 95% CI was constructed and indicates a
statistically significant effect at the 5% level if zero is outside
the interval.
18 In accordance with the literature, we considered
an effect size of approximately 0.2 as small, of approximately
0.5 as moderate and greater than 0.8 as large, with negative
effect sizes indicating worsening. For dichotomous data, OR
Table 1 Study and patient characteristics of trials included for direct comparisons of methotrexate dosages/
routes
Study reference, design and
quality Patient characteristics Treatment groups (methotrexate dosage/route)
Furst et al, 1989
8
Double-blind RCT n = 52 Oral methotrexate 20 mg/m
2/week < 25–35 mg/week
16-Week follow-up RA 4.8 years Oral methotrexate 10 mg/m
2/week < 12.5–20 mg/week
van Tulder score 10 Failed gold or Oral methotrexate 5 mg/m
2/week < 5–10 mg/week
Evidence level 2b D-Penicillamine Placebo
Methotrexate-naive No folic acid
Schnabel et al, 1994
9 n = 185 Oral methotrexate 25 mg/week
Open-label RCT RA 3–10 years Oral methotrexate 15 mg/week
52-Week follow-up Previous DMARD Increase or decrease if necessary
van Tulder score 7 Methotrexate-naive No folic acid
Evidence level 2b
Verstappen et al, 2007
10 n = 299 Fast escalation: oral methotrexate 7.5 mg/week+
Open-label RCT RA ,1 year 5 mg/month to mean max 25 g/week (max 30)
52-Week follow-up DMARD-naive Slow escalation: oral methotrexate 7.5 mg/week+
van Tulder score 7 5 mg/3 months to mean max 18 mg/week
Evidence level 2b Folic acid
Lambert et al, 2004
11 n = 54 Switch to intramuscular methotrexate:
Double-blind RCT RA 10 years 15 mg/week+ escalation 5 mg/month to max 45 mg/week
22-Week follow-up
van Tulder score 9
Evidence level 2b
Failed oral methotrexate
15–20 mg/week
15 mg/week+ placebo escalation
Folic acid
Braun et al, 2008
12
Double-blind RCT
24-Week follow-up
van Tulder score 11
Evidence level 1b
n = 375
RA ,1 years
Methotrexate-naive
Subcutaneous methotrexate 15 mg/week, escalation to
20 mg/week if no ACR20 at 16 weeks
Oral methotrexate 15 mg/week, switch to 15 mg/week
subcutaneously if no ACR20 at 16 weeks
Folic acid
ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; RCT,
randomised controlled trial.
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adverse events. Intention to treat data were used if available.
RESULTS
A total of 1748 references was identified with the systematic
search strategy. After title and abstract screening, 86 articles
were retrieved for full paper review, of which 45 fulfilled the
inclusion criteria. Two congress abstracts, which described a
trial yet to be published
12 and three additional papers from the
hand search, of which one was not found in the databases,
19
were also included. In conclusion, 50 references were included in
the systematic review. A detailed flowchart with excluded
references can be found in appendix 3 of the online only version
of this paper.
The 50 references described 38 original trials, which were
grouped according to the anticipated scenarios. For the optimal
scenario, eight RCT that directly compared oral methotrexate in
different dosages (n = 3),
8–10 intramuscular methotrexate in
different dosages (n = 1),
11 methotrexate oral versus the
subcutaneous route (n = 1),
12 or methotrexate weekly versus
non-weekly (n = 3)
20–22 were found. The suboptimal scenario
included 30 RCT evaluating methotrexate monotherapy versus
placebo (n = 5), DMARD monotherapy (n = 21), combina-
tion therapy (n = 1) or anti-tumour necrosis factor (n = 3)
(references available online only in appendix 4).
Direct comparisons oral methotrexate
Study characteristics
The characteristics of the three RCT that directly compared
different dosages of oral methotrexate are shown in table 1.
8–10
Furst et al
8 evaluated start doses of 5–10 mg/week, 12.5–20 mg/
week and 25–35 mg/week (mean 8, 18 and 32 mg/week,
respectively) in longstanding RA patients who failed other
DMARD. In a similar population, Schnabel et al
9 evaluated a
start dose of 15 or 25 mg/week, with a possible increase or
decrease in the case of insufficient efficacy or toxicity. In
DMARD-naive, early RA patients, Verstappen et al
10 compared
an intensive treatment strategy according to a computerised
model for disease activity with a conventional strategy
according to common practice. This resulted in a fast escalation
of methotrexate from 7.5 mg/week with 5 mg/month to a
mean maximum of 25 mg/week versus a slow escalation of
5 mg/3 months to a mean maximum of 18 mg/week.
Study results
Figure 1B shows a clinical dose–effect relation with effect sizes
ranging from 0–0.45 in the placebo group, 0.60–1.13 in the
methotrexate 5–10 mg/week group, to 0.92–1.41 in the 12.5–
20 mg/week group. Methotrexate 12.5–20 mg/week had a
significantly larger effect than placebo on TJC (pooled effect
size 1.08; 95% CI 0.35 to 1.81), pain (pooled effect size 0.92; 95%
CI 0.21 to 1.64) and global status (pooled effect size 1.58; 95%
CI 0.80 to 2.37), whereas methotrexate 5–10 mg/week only had
a significantly higher effect than placebo on pain and global
status (pooled effect size 0.81; 95% CI 0.05 to 1.57 and 1.26;
95% CI 0.46 to 2.06, respectively). A dose–toxicity relation was
also seen in the OR for patients with adverse events,
gastrointestinal and mucocutaneous toxicity, with the highest
OR for 25–35 mg/week methotrexate (table 2). The pooled
effect size of methotrexate 12.5–20 mg/week versus 5–10 mg/
week ranged from 0.22 to 0.35, indicating an additional effect of
the higher dosed group, although not reaching statistical
significance, whereas no increased toxicity was seen (table 2).
Despite the lack of clinical outcomes, Schnabel et al
9 reported
that 27% of the patients who started with 15 mg/week needed
a dose increase for inefficacy, compared with 3% of those who
started with 25 mg/week (OR 10; 95% CI 2.9 to 33.3). Although
a trend for more gastrointestinal toxicity was observed in the
higher dosed group, the percentage of patients decreasing the
dose due to toxicity was 9% in both groups (table 2). Finally, a
mean tolerable effective dose of 17–20 mg/week was reached.
Larger effect sizes for clinical variables were found for fast
escalation (range 1.38–1.83) than for slow escalation of
Figure 1 Effect sizes (95% CI) of clinical variables per treatment group
of studies directly comparing different dosages/routes. DAS28, disease
activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ,
health assessment questionnaire; im, intramuscular; SJC, swollen joint
count; TJC, tender joint count.
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results (not shown). Differences in effect were significant as
indicated by the pooled effect size for SJC (pooled effect size
0.33; 95% CI 0.10 to 0.56), TJC (pooled effect size 0.43; 95% CI
0.20 to 0.66), pain (pooled effect size 0.47; 95% CI 0.24 to 0.70)
and global status (pooled effect size 0.49; 95% CI 0.26 to 0.72).
Moreover, significantly more ACR50 responses were observed in
the fast escalation group. Although in the fast escalation group
significantly more patients experienced adverse events, the
nature of the events was similar (table 2).
Only Verstappen et al
10 and Schnabel et al
9 reported
radiological outcomes. In Verstappen et al
10 no additional effect
on radiological progression was seen of the fast in comparison
with the slow escalation group (pooled effect size 0.05; 95% CI
20.23 to 0.33), whereas in Schnabel et al
9 25 mg/week versus
15 mg/week gave an OR of 0.4 (95% CI 0.1 to 2.0) for the
progression of joint damage in a selection of patients with less
than 3 years disease duration.
Direct comparisons parenteral methotrexate
Study characteristics
Two RCT were found that evaluated parenteral methotrexate
(table 1).
11 12 longstanding RA patients who had failed on 15–
20 mg/week oral methotrexate and were switched to 15 mg/
week intramuscular methotrexate for 6 weeks, without achiev-
ing a DAS28 response, Lambert et al
11 evaluated subsequent
intramuscular placebo versus intramuscular methotrexate esca-
lation up to 45 mg/week. In contrast, Braun et al
12 compared
start doses of methotrexate 15 mg/week subcutaneously versus
orally in methotrexate-naive, early RA patients.
Study results
Small to moderate effect sizes for clinical variables were found
in the methotrexate escalation group (range 0.09–0.67) and the
placebo escalation group (range 20.22–0.82), without any
significant differences between the groups (fig 1C). SRM
showed similar results (not shown). The pooled effect size
ranged from 20.38 in favour of the placebo group to 0.33 in
favour of the escalation group. The ACR20 response in both
groups was low (4%) and toxicity was similar (table 2).
In contrast, significantly more patients who started sub-
cutaneous methotrexate in Braun et al
12 achieved an ACR20
response than those who started oral methotrexate (85% vs
77%, respectively, OR 1.7; 95% CI 1.01 to 2.9) after 16 weeks. A
trend for more ACR20 (OR 1.5; 95% CI 0.96 to 2.4) and ACR70
response (OR 1.4; 95% CI 0.9 to 2.1) after 24 weeks was also
seen. However, patients on subcutaneous methotrexate more
often discontinued therapy due to toxicity, without differences
in the type of adverse event, including gastrointestinal toxicity
(table 2).
Indirect comparisons
Indirect comparisons of the methotrexate arms of 30 trials
grouped per comparator drug revealed uninformative, as
methotrexate dosages or routes were not different, the clinical
response to the comparator drugs showed large heterogeneity
and outcome measures were not uniform. A summary is
available in appendix 4 online only.
Direct comparisons methotrexate frequencies
In addition to the primary research question, three RCT directly
comparing oral methotrexate weekly versus non-weekly were
identified and included.
20–22 The results can be found in appendix
5 available online only.
DISCUSSION
This systematic review summarises and evaluates the available
evidence from the literature on the optimal dosage and route of
administration of methotrexate in RA. Combined with the
expert opinion of a broad panel of rheumatologists in the 3E
Initiative, the results served as an evidence base for generating
one of the 10 clinical recommendations for the use of
methotrexate in rheumatic diseases. A detailed description of
all final recommendations can be found elsewhere.
4
The results showed that start doses of 25 mg/week orally or
fast dose escalation with 5 mg/month to 25–30 mg/week were
associated with higher efficacy, but also with more toxicity, in
comparison with start doses of 5–15 mg/week or slow escala-
tion with 5 mg/3 months.
8–10 These results strongly support
reaching high (25–30 mg/week) doses in a short period of time
for efficacy, but with toxicity as a limiting factor. The mean
tolerable effective dose of 17–20 mg/week, after adjusting from
15 or 25 mg/week starting dose in Schnabel et al,
9 emphasises
this efficacy/toxicity ratio. However, two of the reviewed
studies lacked folic acid supplementation, which might increase
the tolerability of higher dosages of methotrexate. As investi-
gated concurrently in the 3E Initiative as a separate question, a
meta-analysis of nine RCT indicated that folic acid reduces
gastrointestinal and liver toxicity, without reducing efficacy.
23
Therefore, as the primary aim of current RA treatment is
achieving adequate undelayed disease control, the optimal
evidence-based dosing strategy seems to be: starting with
15 mg/week and escalating fast with 5 mg/month to 25–
30 mg/week, although this should always be individually
adapted to the level of disease activity and tolerability, including
renal function.
24
Although oral methotrexate is widely preferred, because of
patients’ preferences and low costs, the bioavailability of
parenteral methotrexate is higher with increasing doses.
25 26
Whether this leads to increased efficacy is addressed in only
one RCT, which suggests that methotrexate 15 mg/week
subcutaneously is indeed associated with a better response
compared with 15 mg/week orally.
12 However, escalating the
oral dose to 25 mg/week might also have increased clinical
efficacy in this trial. This is supported by data from observa-
tional studies, in which patients switching from parenteral to
oral methotrexate at an equal dose showed disease exacerba-
tions, but not if the oral dose was 2.5–5 mg/week higher.
27 28 In
contrast, in longstanding RA patients who failed 15–20 mg/
week oral methotrexate plus other DMARD, neither a switch to
15 mg/week intramuscularly, nor subsequent intramuscular
dose escalation resulted in increased efficacy.
11 However, for
this selected population not responding well to conventional
DMARD, therapy with biologicals is currently indicated.
29 The
evidence on toxicity associated with the parenteral use of
methotrexate is inconsistent. Whereas more withdrawal due to
toxicity, but similar adverse events were seen in the RCT from
Braun et al,
12 observational data suggest a decrease in (gastro-
intestinal) side effects administering methotrexate parenter-
ally.
27 28 Therefore, in summary, the preferred route of
methotrexate seems to be oral, but a switch to subcutaneous
is suggested in the case of an insufficient response at the highest
tolerable oral dose.
The frequency of weekly dosing of methotrexate was
inherited from the dermatological experience in the early
1980s. As the half-life of the active polyglutamate is 3 days, a
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and less toxic, although it would also be less practical.
30
However, Pandya et al
22 showed that a twice weekly schedule
of methotrexate had no advantage over a weekly schedule. In
contrast, a change to every other week dosing was possible in
patients stable or in remission on methotrexate, although some
experienced disease flares.
20 21 In conclusion, weekly methotrex-
ate is the preferred frequency of administration, with a
potential switch to a fortnightly schedule in the case of
sustained remission.
In this systematic review, we aimed at finding all available
evidence on the optimal dosage and route of methotrexate, by
using a strict methodological search and selection strategy.
5
Furthermore, we limited the search to RCT only, as this design
would potentially yield the highest level of evidence without
bias from lack of randomisation or blinding, which is associated
with observational studies. Moreover, indirect comparisons
between methotrexate arms of trials versus placebo, DMARD
or anti-tumour necrosis factor, were uninformative in this
review, suggesting that observational data would be even more
difficult to interpret. In conclusion, eight out of 38 included
RCT directly addressed the research question and provided level
1b–2b evidence for the efficacy and toxicity of various dosages
and routes of methotrexate.
In conclusion, taking patient characteristics into account, a
start dose of 15 mg/week orally, escalating with 5 mg/month to
25–30 mg/week or the highest tolerable dose, with a subsequent
switch to subcutaneous administration in the case of an
insufficient response, seems to be the optimal evidence-based
dosing and routing strategy for methotrexate in RA. This
conclusion was incorporated as one of the recommendations of
the 3E Initiative for the use of methotrexate in rheumatic
diseases.
4
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